Your browser doesn't support javascript.
loading
Influence of Physiological Variables and Comorbidities on Plasma Aß40, Aß42, and p-tau181 Levels in Cognitively Unimpaired Individuals.
Martínez-Dubarbie, Francisco; Guerra-Ruiz, Armando; López-García, Sara; Irure-Ventura, Juan; Lage, Carmen; Fernández-Matarrubia, Marta; Pozueta-Cantudo, Ana; García-Martínez, María; Corrales-Pardo, Andrea; Bravo, María; Martín-Arroyo, Juan; Infante, Jon; López-Hoyos, Marcos; García-Unzueta, María Teresa; Sánchez-Juan, Pascual; Rodríguez-Rodríguez, Eloy.
Afiliación
  • Martínez-Dubarbie F; Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Guerra-Ruiz A; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • López-García S; Biochemistry and Clinical Analysis Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Irure-Ventura J; Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Lage C; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Fernández-Matarrubia M; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Pozueta-Cantudo A; Immunology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • García-Martínez M; Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Corrales-Pardo A; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Bravo M; Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute, University of California, San Francisco, CA 94143, USA.
  • Martín-Arroyo J; Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Infante J; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • López-Hoyos M; Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • García-Unzueta MT; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Sánchez-Juan P; Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Rodríguez-Rodríguez E; Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Int J Mol Sci ; 25(3)2024 Jan 25.
Article en En | MEDLINE | ID: mdl-38338759
ABSTRACT
Plasma biomarkers for Alzheimer's disease (AD) are a promising tool that may help in early diagnosis. However, their levels may be influenced by physiological parameters and comorbidities that should be considered before they can be used at the population level. For this purpose, we assessed the influences of different comorbidities on AD plasma markers in 208 cognitively unimpaired subjects. We analyzed both plasma and cerebrospinal fluid levels of Aß40, Aß42, and p-tau181 using the fully automated Lumipulse platform. The relationships between the different plasma markers and physiological variables were studied using linear regression models. The mean differences in plasma markers according to comorbidity groups were also studied. The glomerular filtration rate showed an influence on plasma Aß40 and Aß42 levels but not on the Aß42/Aß40 ratio. The amyloid ratio was significantly lower in diabetic and hypertensive subjects, and the mean p-tau181 levels were higher in hypertensive subjects. The glomerular filtration rate may have an inverse relationship on plasma Aß40 and Aß42 levels but not on the amyloid ratio, suggesting that the latter is a more stable marker to use in the general population. Cardiovascular risk factors might have a long-term effect on the amyloid ratio and plasma levels of p-tau181.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Péptidos beta-Amiloides / Enfermedad de Alzheimer Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: España